Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 905-357-4 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Remarks:
- (LLNA: BrdU)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 May 2016 - 22 December 2016
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- This information is used for Geranyl Isobutyrate MCS.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 017
- Report date:
- 2017
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442B (Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA)
- Version / remarks:
- 22 July 2010
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- mouse local lymph node assay (LLNA): BrdU-ELISA
Test material
- Reference substance name:
- Citronellyl butyrate
- EC Number:
- 205-463-4
- EC Name:
- Citronellyl butyrate
- Cas Number:
- 141-16-2
- Molecular formula:
- C14H26O2
- IUPAC Name:
- 3,7-dimethyloct-6-en-1-yl butyrate
Constituent 1
In vivo test system
Test animals
- Species:
- mouse
- Strain:
- other: CBA/N
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Japan SLC, Inc., Japan (producer); Central Lab. Animal Inc., Republic of Korea (Supplier)
- Females (if applicable) nulliparous and non-pregnant: not specified]
- Age at study initiation: 9 - 12 weeks
- Weight at study initiation: 18.5 - 21.0g (dose range finding); 17.6 - 21.7g (main set1); 19.1 - 25.7g (main set2)
- Housing: Group housing 2–3 animals/Polysulfone cage
- Diet: free access to Pelleted rodent chow (Teklad Certified Irradiated Global 18% Protein Rodent Diet 2918C)
- Water: free access to public tap water filtered and irradiated by ultraviolet light
- Acclimation period: 4 days
- Indication of any skin lesions: no
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.1 - 24.7
- Humidity (%): 44.5 - 65
- Air changes (per hr): 10 - 15
- Photoperiod (hrs dark / hrs light): 12/12
- IN-LIFE DATES: From: 31 May 2016 To: 21 December 2016
Study design: in vivo (LLNA)
- Vehicle:
- acetone/olive oil (4:1 v/v)
- Concentration:
- 0, 25, 50 and 100% (set 1); 0, 1, 5 and 10% (set 2)
- No. of animals per dose:
- 5
- Details on study design:
- PRE-SCREEN TESTS:
- Compound solubility: the test substance was dissolved in the vehicle in a preliminary solubility test.
- Two animals were observed per dose group. All mice were observed daily for any clinical signs of systemic toxicity or local irritation at the application site. Body weights were recorded prior to dosing (Day 1) and on the day of necropsy, Day 6. Both ears of each mouse were observed for erythema and scored using erythema score. Ear thickness measurement was taken using a thickness gauge on Day 1 (predose), Day 3 and Day 6. Additionally, on Day 6, ear weight was determined by balance.
MAIN STUDY : the main study was conducted in two sets, with lower treatment doses used in the second set.
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: Following the quarantine-acclimation period (group assignment), 25 healthy females were selected and randomly distributed into 5 groups (5 females per group).
- Criteria used to consider a positive response: SI ≥ 1.6
TREATMENT PREPARATION AND ADMINISTRATION: A volume of 25 μL was applied to the dorsum of both ears of all animals daily for three consecutive days. The dose level of the positive substance was selected at 25%. Negative control animals were dosed with the vehicle, acetone/olive oil solution.
OBSERVATIONS:
- Clinical signs: All animals were observed for mortality, general condition and clinical signs for 6 days.
- Body weights: Body weights were recorded prior to dosing (day 1) and on the day of necropsy (day 6).
- Erythema: Both ears of each mouse were observed for erythema and scored for 6 days.
- Ear thickness: Ear thickness measurement was taken using a thickness gauge (543-681B, Mitutoyo Co., Japan) on day 1 (pre-dose), day 3 (approximately 48 hours after the first dose) and day 6 (the day of necropsy).
On day 5, a volume of 0.5 mL (5 mg/mouse) of BrdU (10 mg/mL) solution was injected interperitoneally. Approximately 24 hours (24 h) after BrdU injection, the animals were euthanized under CO2 gas. The draining auricular lymph nodes from each mouse ear were excised and processed separately in phosphate buffered saline for each animal.
Preparation of cell suspension:
For each mouse, a single-cell suspension of lymph node cells (LNC) excised bilaterally was prepared by #70 nylon mesh to generate a single cell suspension. In each case, the target volume of the LNC suspension was adjusted to the determined optimized volume. The optimized volume was based on the mean absorbance within 0.1-0.2 in the NC group.
Determination of cellular proliferation: BrdU was measured by ELISA: 100 μL of the LNC suspension was added to the wells of a flat-bottom microplate in triplicate. After fixation and denaturation of the LNC suspension, anti-BrdU antibody was added to each well and allowed to react. Subsequently, anti-BrdU antibody was removed by washing and the substrate solution was then added and allowed to produce chromogen. Absorbance at 370 nm with a reference wavelength of 492 nm was measured.
BrdU labelling index = (ABSem - ABSblank,em) - (ABSref-ABSblank,ref)
with ABS = Absorption; em = emission wavelength; ref= reference substance
SI= mean of BrdU labelling index in the test substance / mean of BrdU labelling index in the negative control
Acceptability criterium: positive control should have a SI ≥ 1.6.
Evaluation criteria:
SI Result
SI < 1.6 Negative
SI ≥ 1.6 Positive - Positive control substance(s):
- hexyl cinnamic aldehyde (CAS No 101-86-0)
- Statistics:
- Statistical analysis was conducted using a statistical program (version 9.3, SAS Institute Inc., U.S.A.) for the data including body weight, erythema score, ear thickness, ear weight and stimulation index.
Bartlett’s test was employed on homogeneity of variance (significance level: 0.05) for body weights, ear thickness, ear weight and stimulation index data. One-way analysis of variance (ANOVA) was employed on homogeneous data. Dunnett’s t-test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the negative control group (G1, G6) and each of the test substance groups (G2–G4, G7–G9) or positive substance group (G5, G10). Since it was not significant, Kruskal-Wallis test was employed on heterogeneous data and Steel’s test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the
negative control group (G1, G6) and each of the test substance groups (G2–G4, G7–G9) or positive substance group (G5, G10).
Kruskal-Wallis test for the erythema score was employed on heterogeneous data, and Steel’s test was applied for multiple comparisons (significance levels: 0.05 and 0.01, one-tailed) between the negative control group (G1, G6) and each of the test substance groups (G2–G4, G7–G9) or positive substance group (G5, G10).
Results and discussion
- Positive control results:
- Set 1: In the positive control group at 25%, the mean value of stimulation index was 3.10. There was a significant increase when compared to the negative control group (p<0.05).
Set 2: In the positive control group at 25%, the mean value of stimulation index was 4.32. There was a significant increase when compared to the negative control group (p<0.05).
In vivo (LLNA)
Resultsopen allclose all
- Key result
- Parameter:
- other: EC1.6 (%)
- Value:
- 26.4
- Key result
- Parameter:
- SI
- Value:
- 1.22
- Remarks on result:
- other: Test group: 1%
- Key result
- Parameter:
- SI
- Value:
- 1.1
- Remarks on result:
- other: Test group: 5%
- Key result
- Parameter:
- SI
- Value:
- 1.4
- Remarks on result:
- other: Test group: 10%
- Key result
- Parameter:
- SI
- Value:
- 1.78
- Remarks on result:
- other: Test group: 25%
- Key result
- Parameter:
- SI
- Value:
- 2.15
- Remarks on result:
- other: Test group: 50%
- Key result
- Parameter:
- SI
- Value:
- 1.7
- Remarks on result:
- other: Test group: 100%
- Cellular proliferation data / Observations:
- DETAILS ON STIMULATION INDEX CALCULATION
- Set 1: In the negative control group, the mean value of stimulation index was 1.00. In the test substance groups at 25, 50 and 100%, the mean values of stimulation index were 1.78, 2.15 and 1.70, respectively. There were significant increases when compared to the negative control group (p<0.05: 25, 50 and 100%).
- Set 2: In the negative control group, the mean value of stimulation index was 1.00. In the test substance groups at 1, 5, 10%, the mean values of stimulation index were 1.22, 1.10 and 1.40, respectively. There were no significant differences when compared to the negative control group.
EC1.6 CALCULATION
Three concentration showed SI of <1.6, and EC1.6 was calculated to be 26.4%.
CLINICAL OBSERVATIONS: There were no abnormal clinical signs or deaths in any dosing group during the observation period in both experiments.
BODY WEIGHTS (mean)
- Set 1:
In the negative control group, the mean values of body weights were 19.3–20.2 g prior to dosing until Day 6 after dosing.
In the test substance groups at 25, 50 and 100%, the mean values of body weights were 19.1–19.5, 19.5–19.6 and 19.3–19.3 g, respectively. There were no significant differences when compared to the negative control group.
In the positive control group at 25%, the mean values of body weights were 19.6–19.9 g. There were no significant differences when compared to the negative control group.
- Set 2:
In the negative control group, the mean values of body weights were 21.1–21.3 g prior to dosing until Day 6 after dosing.
In the test substance groups at 1, 5, 10%, the mean values of body weights were 21.7–21.4, 21.6–20.6 and 21.9–20.8 g, respectively. There were no significant differences when compared to the negative control group.
In the positive control group at 25%, the mean values of body weight were 21.4–20.9 g. There were no significant differences when compared to the negative control group.
ERYTHEMA SCORE:
- Set 1:
In the negative control group, the mean values of erythema score at 0.0 from prior to dosing until Day 6 after dosing.
In the test substance groups at 25, 50 and 100%, the mean values of erythema score was 0.0–0.7, 0.0–0.9 and 0.0–1.2, respectively. There were significant increases when compared to the negative control group (p<0.05: Day 4 (25%), p<0.01: Days 4 (50 and 100%), 5 and 6 (25, 50 and 100%)).
In the positive control group at 25%, the mean values of erythema score was 0.0–1.9. There were significant increases when compared to the negative control group (p<0.01: Days 3, 4, 5 and 6).
- Set 2:
In the negative control group, the mean values of erythema score at 0.0 prior to dosing until Day 6 after dosing.
In the test substance groups at 1, 5, 10%, the mean values of erythema was 0.0, 0.0–1.1 and 0.0–1.0, respectively. There were significant increases when compared to the negative control group (p<0.01: Days 5 and 6 (5 and 10%)).
In the positive control group at 25%, the mean values of erythema score was 0.0–1.7. There was a significant increase when compared to the negative control group (p<0.01: Days 3, 4, 5 and 6).
EAR THICKNESS (mean):
- Set 1:
In the negative control group, the mean values of ear thickness at 0.19–0.20 mm prior to dosing until Day 6 after dosing.
In the test substance groups at 25, 50 and 100%, the mean values of ear thickness was 0.19–0.21, 0.20–0.21 and 0.19–0.21 mm, respectively. There were significant increases when compared to the negative control group (p<0.05: Day 6 (25%)).
In the positive control group at 25%, the mean value of ear thickness was 0.19–0.22 mm. There were significant increases when compared to the negative control group (p<0.01: Day 6).
- Set 2:
In the negative control group, the mean values of ear thickness at 0.19–0.19 mm prior to dosing until Day 6 after dosing.
In the test substance groups at 1, 5, 10%, the mean values of ear thickness were 0.20–0.19, 0.20–0.20, 0.20–0.20 mm, respectively. There was a significant increase when compared to the negative control group (p<0.05: Day 1 (1%), Day 3 (5%), p<0.01: Days 1 (5 and 10%), 3 (10%) and 6 (5 and 10%)).
In the positive control group at 25%, the mean value of ear thickness was 0.20–0.21 mm. There was a significant increase when compared to the negative control group (p<0.01: Days 1, 3 and 6).
EAR WEIGHTS (mean):
- Set 1:
In the negative control group, the mean value of ear weight was 12.6 mg.
In the test substance groups at 25, 50 and 100%, the mean values of ear weight were 13.5, 13.5 and 13.7 mg, respectively. There were significant increases when compared to the negative control group (p<0.05: 100%).
In the positive control group at 25%, the mean value of ear weight was 14.2 mg. There was a significant increase when compared to the negative control group (p<0.01).
- Set 2:
In the negative control group, the mean value of ear tissue was 12.1 mg.
In the test substance groups at 1, 5, 10%, the mean values of ear tissue were 12.9, 13.3 and 12.6 mg, respectively. There were significant increases when compared to the negative control group (p<0.05: 5%).
In the positive control group at 25%, the mean value of ear tissue was 13.9 mg. There was a significant increase when compared to the negative control group (p<0.01).
Applicant's summary and conclusion
- Interpretation of results:
- other: Skin sensitiser Category 1B
- Remarks:
- according to EU CLP (EC No. 1272/2008 and its amendments).
- Conclusions:
- The substance produced a SI ≥ 1.6 and an EC1.6 value of 26.4% was calculated. Based on these results, the substance is considered to be a skin sensitiser.
- Executive summary:
In a Local Lymph Node Assay (BrdU-ELISA), the skin sensitisation potential of the substance was tested according to OECD TG 442B under GLP. Per concentration, 5 female mice were used. Skin sensitization potential was evaluated by ear thickness measurements. Cellular proliferations and SI were determined. In the first set, at 25, 50 and 100%, SI values were 1.78, 2.15 and 1.70, respectively. In the second set, at 1, 5 and 10%, SI values were 1.22, 1.10 and 1.40, respectively. Negative and positive controls were included and all acceptability criteria were met (SI values positive controls: 3.10 and 4.32). These results show that the substance could elicit a SI ≥ 1.6. An EC1.6 value of 26.4% was calculated. Based on the results, the substance is considered a skin sensitiser 1B.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.